Accordingly, earlier studies indicate that a genetic deficiency of TWEAK or Fn14 [23], or treatment with either monoclonal antibodies against TWEAK [18] or with a soluble Fn14-Fc-decoy receptor [5] are associated with improved neurological outcome following experimental cerebral ischemia. This evidence concerns the gene TNFRSF12A and Cerebral ischemia.